Biovica International AB Class B (BIOVIC.B) AI Stock Analysis

• Market Cap: €67.76M
• Dividend Yield: N/A
• Average Volume (3M): 258.43K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: 36.91%
• EPS Growth: 49.66%
• Country: SE
• Employees: 26
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -0.32
• Shares Outstanding: 84,073,710
• 10 Day Avg. Volume: 301,199
• 30 Day Avg. Volume: 258,428
• PEG Ratio: -0.04
• Price to Book (P/B): 1.09
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: kr1.00 ▲(33.33%Upside)

Biovica International AB Class B's overall stock score is primarily impacted by its financial performance and technical analysis. The company's revenue growth is overshadowed by profitability challenges and negative cash flows. Technical indicators suggest a neutral to slightly negative outlook, while valuation metrics highlight ongoing financial difficulties. The absence of earnings call data and notable corporate events means these factors do not influence the score.

Biovica International AB Class B Business Overview & Revenue Model

Company Description

Biovica International AB Class B (BIOVIC.B) is a biotechnology company focused on developing and commercializing diagnostic tests aimed at improving cancer treatment outcomes. The company's core product, DiviTum, is a blood-based biomarker assay designed to measure cell proliferation rates, providing valuable insights into the effectiveness of cancer therapies. Biovica operates primarily within the healthcare sector, leveraging cutting-edge technology to enhance cancer diagnostics and treatment monitoring.

How the Company Makes Money

Biovica International AB makes money through the development and sale of its diagnostic products, primarily its flagship product, DiviTum. Revenue is generated from the sale of DiviTum kits to healthcare providers, research institutions, and pharmaceutical companies. The company may also earn income from collaborations, partnerships, and licensing agreements with other biotech and pharmaceutical companies aimed at integrating its diagnostic solutions into broader cancer treatment regimens. Additionally, Biovica may seek to participate in joint ventures or receive grants and funding to support its research and development efforts, further contributing to its revenue streams.

Biovica International AB Class B Financial Statement Overview

Summary

Biovica International AB Class B is in a growth phase with increasing revenue, but it faces significant profitability and cash flow challenges. The stable capital structure with low debt levels is a positive, yet the company struggles to achieve positive net income and cash flows, highlighting a need for better operational efficiency.

Income Statement

Biovica International AB Class B has shown consistent revenue growth over the years, with a notable increase from SEK 2.04 million in 2022 to SEK 8.19 million in TTM. However, the company struggles with negative profitability, indicated by a negative gross profit margin and net profit margin. The EBIT and EBITDA margins are also deeply negative, reflecting high operational losses.

Balance Sheet

The company maintains a relatively stable equity position, with a debt-to-equity ratio of 0.09, indicating low leverage. However, the return on equity is negative due to ongoing net losses. The equity ratio remains healthy, suggesting a strong capital structure.

Cash Flow

Biovica faces significant cash flow challenges, with negative free cash flow and operating cash flow. The operating cash flow to net income ratio is near 1, indicating that cash flow issues align with reported losses. Additionally, free cash flow has been consistently negative, highlighting ongoing financial strain.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
8.19M	7.29M	3.38M	2.04M	2.08M	1.67M
	Gross Profit
-35.85M	6.88M	4.62M	4.67M	5.27M	8.49M
	EBIT
-106.98M	-126.84M	-110.46M	-60.10M	-40.18M	-29.82M
	EBITDA
-97.69M	-119.51M	-105.96M	-53.47M	-36.56M	-25.65M
	Net Income Common Stockholders
-106.39M	-124.82M	-110.49M	-60.00M	-39.48M	-30.32M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
867.00K	79.41M	114.33M	89.79M	145.36M	40.78M
	Total Assets
28.73M	131.41M	172.29M	151.63M	192.65M	90.26M
	Total Debt
0.00	7.83M	10.45M	13.25M	2.42M	3.45M
	Net Debt
-867.00K	-71.58M	-103.87M	-64.17M	-142.93M	-37.32M
	Total Liabilities
4.00M	34.77M	33.65M	27.54M	9.99M	12.04M
	Stockholders Equity
24.55M	96.64M	138.63M	124.09M	182.66M	78.22M
Cash Flow		Free Cash Flow
-93.15M	-114.72M	-97.42M	-55.52M	-37.97M	-31.82M
	Operating Cash Flow
-92.79M	-114.58M	-94.64M	-52.13M	-34.41M	-24.78M
	Investing Cash Flow
-354.00K	-585.00K	-2.78M	-3.40M	-3.56M	-7.04M
	Financing Cash Flow
30.99M	79.50M	122.01M	-136.00K	142.66M	55.74M

Biovica International AB Class B Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOVIC.B, the sentiment is Neutral. The current price of 0.75 is below the 20-day moving average (MA) of 0.79, below the 50-day MA of 0.80, and below the 200-day MA of 1.74, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 46.77 is Neutral, neither overbought nor oversold. The STOCH value of 25.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:BIOVIC.B.

Biovica International AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
BIOVIC.B	51 Neutral	€67.76M	―	-104.90%	―	36.91%	49.66%
NICA	45 Neutral	kr106.03M	―	-151.10%	―	230.57%	46.64%
SPAGO	38 Underperform	kr69.64M	―	-105.78%	―	58.72%	70.69%
BIOSGN	34 Underperform	kr144.65M	―	-56.71%	―	―	35.61%
ACTI	32 Underperform	kr293.39M	―	-186.40%	―	―	24.47%